AstraZeneca (LON:AZN)‘s stock had its “hold” rating reissued by research analysts at Liberum Capital in a report issued on Friday.

Several other research analysts have also commented on AZN. UBS Group reaffirmed a “neutral” rating and issued a GBX 5,900 ($77.09) price target on shares of AstraZeneca in a report on Monday, November 19th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a report on Monday, November 19th. Barclays reaffirmed an “overweight” rating and issued a GBX 6,800 ($88.85) price target on shares of AstraZeneca in a report on Monday, November 19th. Shore Capital reaffirmed a “hold” rating on shares of AstraZeneca in a report on Tuesday, October 30th. Finally, BNP Paribas set a GBX 6,500 ($84.93) price target on shares of AstraZeneca and gave the company a “buy” rating in a report on Tuesday, September 11th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of GBX 5,927.44 ($77.45).

LON AZN opened at GBX 5,955 ($77.81) on Friday. AstraZeneca has a one year low of GBX 4,260 ($55.66) and a one year high of GBX 5,520 ($72.13).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: Understanding Analyst Ratings

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.